RxDoctor Payments Data

Rodney Perez, MD

Gastroenterology · Asheville, NCNPI 1578553541

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Ambu A/s at 44.4% of the total. That places this record below the midpoint for gastroenterology clinicians in NC, where the typical reported total is $1,694.

$1,668in general payments, 2019–2025

Across 43 payments — averaging $38.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ambu A/s$740
  • AbbVie$280
  • Takeda Pharmaceuticals U.S.A., Inc.$188
  • QOL Medical, LLC$62
  • Olympus America Inc.$55
  • Ironwood Pharmaceuticals, Inc$55
  • plus $289 from 10 others
$4,133in research payments, 2019–2025

Across 1 payment — averaging $4132.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$4K

What the payments were for

  • Speaking & faculty fees$86552%
  • Food & beverage$78747%
  • Education$161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,668 in reported general payments places this provider in the 45th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$322,874
Medicare patients
529
Services billed
11,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$34,553
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag27$3,292
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates28$2,069
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl90$1,761
Omeprazole60$452
Pantoprazole Sodium44$429
Famotidine16$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$280$34,55315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Asheville

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →